Low-Dose rituximab shows promise for blood disorder
NCT ID NCT01719692
First seen Feb 18, 2026 · Last updated May 24, 2026 · Updated 11 times
Summary
This study tested two low-dose rituximab schedules in 100 adults with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The goal was to see if these regimens could safely raise platelet counts and reduce bleeding. The approach aims to control the disease, not cure it, as ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIC PURPURA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hospital of Blood disease
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.